CMO Image Blog Article

What’s New in the Biologics CMO Space in APAC?

by

Excerpt: As more biologics products enter and exit clinical development and into the market in the APAC region, the opportunities for CMOs to fulfil production requirements are burgeoning. There is an increase in demand for innovative process technologies to meet the demand. Biopharmaceutical companies in APAC are moving away from in-house manufacturing and recruiting CMOs […]

cell therapy blog image

Notable Players in the APAC Cell Therapy Manufacturing Space

by

Excerpt Key drivers such as fund and regulatory support from the government, improved market access and healthcare infrastructure and more are currently fueling growth in APAC’s cell therapy market. The enactment of the Act on the Safety and Support of Advanced Regenerative Medical Treatment and Medicine in August 2020, the increased market access can be […]

Cytovia-Therapeutics-Logo

Cytovia Therapeutics and its Newly Formed China-Focused CytoLynx Joint Venture Raise $45 Million to Advance NK Cell Therapy Pipeline

by

Excerpt $45 million in financing has been secured by Cytovia and its China-focused joint venture CytoLynx, to advance their Natural Killer (NK) cell therapy for global commercialisation. TF Capital, together with Cytovia, have formed CytoLynx, and the venture is further supported by YF Capital, BioTrack Capital, Ruihua Capital and YG Sino-Dragon Fund. This will accelerate […]

Ixaka announces positive interim Phase 3 clinical trial data for its lead cell therapy candidate REX-001

Ixaka announces positive interim Phase 3 clinical trial data for its lead cell therapy candidate REX-001

by

Excerpt Positive interim analysis of safety and efficacy from the first 30% of enrolled patients evaluated 12 months post-treatment in a Phase 3 clinical trial (SALAMANDER) of REX-001 has resulted in the independent Data Monitoring Committee (DMC) recommending the unchanged continuation of the trial. REX-001, an autologous multi-cell therapy (MCT), is being developed for the […]

Tree Frog Therapeutics Blog

TreeFrog Therapeutics secures $75m in Series B financing to advance a pipeline of Stem Cell-Derived cell therapies and deploy proprietary C-Stem™ technology in the USA & Japan

by

Excerpt Pursuant to securing $75 million in Series B funding, TreeFrog Therapeutics names Frederic Desdouits, PhD, as CEO and announces that co-founder Kevin Alessandri, PhD, is to relocate to Boston to drive TreeFrog’s expansion in the U.S. The funding was led by Bpifrance Large Venture, together with Leonard Green & Partners L.P., Bristol Myers Squibb […]

Updated Biothera Blog

Bio-Thera Solutions Announces Commercialization and License Agreement for BAT1706, a Proposed Biosimilar Referencing Avastin® (Bevacizumab)

Excerpt Bio-Thera Solutions and Sandoz have entered a commercialisation and license agreement for BAT1706, a monoclonal antibody that is a proposed biosimilar referencing AVASTIN® (bevacizumab). Under the terms of the agreement, Bio-Thera will develop, manufacture and supply BAT1706 and Sandoz will market the bevacizumab biosimilar in markets covered by the agreement.  Article Bio-Thera Solutions has […]

Adaptimmune Enters into a Strategic Collaboration with Genentech

Adaptimmune Enters into a Strategic Collaboration with Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies

Excerpt An agreement between Adaptimmune and Genentech is set to drive “off-the-shelf” cancer-targeted cell therapy advancements and commercialization with an initial payment of $150 million to Adaptimmune. The partnership also aims to develop a first-of-its-kind personalized cell therapy platform to enable patients to receive curated T-cell products for their individual cancer treatment needs. Adaptimmune may […]

AbbVie and REGENXBIO Announce Eye Care Collaboration

AbbVie and REGENXBIO Announce Eye Care Collaboration

Excerpt AbbVie will make an upfront $370 million payment to REGENXBIO as part of a recently announced partnership to develop and commercialize a gene-therapy under investigation. Trials are on-going for RGX-314 as a one-time treatment for wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal diseases. The global development and outreach […]

Stem Cells for Everyone: I Peace expands its clinical-grade iPSC banking service leveraging mass manufacturing capability

Excerpt I Peace is expanding its proprietary clinical-grade induced pluripotent stem cell (iPSC) banking service – first by improving accessibility across Japan through a collaboration with I’rom Group, and then expanding to global markets including the U.S. Leveraging an increased mass manufacturing capability and reduced costs with the development of a novel system, the company […]

FUJIFILM Diosynth Biotechnologies and NeuExcell Therapeutics enter manufacturing agreement to rapidly advance NXL-001, a potential neuro-regeneration gene therapy to treat ischemic cortical stroke

FUJIFILM Diosynth Biotechnologies and NeuExcell Therapeutics enter manufacturing agreement to rapidly advance NXL-001, a potential neuro-regeneration gene therapy to treat ischemic cortical stroke

Excerpt The two companies have entered a manufacturing agreement for NXL-001, under which FUJIFILM will be tasked with providing essential drug substance and drug product manufacturing under accelerated timelines at its manufacturing facility in College Station, Texas, for NeuExcell’s first in-human clinical studies. This will hopefully facilitate a possible treatment for patients suffering from ischemic […]

Generate Life Sciences Logo

Generate Life Sciences Establishes Newborn Stem Cell Manufacturing Facility to Support the Development of Personalized Therapeutics

by Kashmiira Nayar

Generate Life Sciences Establishes Newborn Stem Cell Manufacturing Facility to Support the Development of Personalized Therapeutics Generate Life Sciences, the largest private newborn stem cell biorepository in the world, announced the establishment of its Good Manufacturing Practice (GMP) facility in La Jolla, California, to manufacture newborn stem cell biologics. This bolsters the company’s existing stem cell research […]

Cellares-Cell-Shuttle-150x150

Cellares and Poseida Therapeutics Partner to Accelerate Cell Therapy Manufacturing

by Kashmiira Nayar

Cellares and Poseida Therapeutics Partner to Accelerate Cell Therapy Manufacturing Clinical-stage biopharmaceutical company Poseida Therapeutics has joined life sciences technology company Cellares Corporation’s Early Access Partnership Program (EAPP), making it the third organisation to participate.  Through the program, Poseida gets visibility and access to Cellares’ Cell Shuttle and will help to advance its development, range […]

bag